523 results on '"DeConde, Adam"'
Search Results
2. Pro-inflammatory markers associated with COVID-19-related persistent olfactory dysfunction.
- Author
-
Jang, Sophie, Pak, Kwang, Strom, Allyssa, Gomez, Leslie, Kim, Kyubo, Doherty, Taylor, DeConde, Adam, Ryan, Allen, and Yan, Carol
- Subjects
COVID‐19 ,long haulers ,mucus ,olfactory dysfunction ,persistent smell loss ,pro‐inflammatory ,Humans ,COVID-19 ,Prospective Studies ,Smell ,Cytokines ,Biomarkers ,Olfaction Disorders - Abstract
INTRODUCTION: While localized inflammation has been implicated in the pathophysiology of acute coronavirus disease of 2019 (COVID-19) olfactory dysfunction (OD), persistent COVID-19 OD remains poorly understood with limited therapeutics. Our prospective study evaluated olfactory cleft (OC) biomarkers as predictors of persistent OD in mucus sampling. METHODS: COVID-19 subjects with persistent OD >3 months confirmed by psychophysical olfaction tests were compared to COVID-19 subjects with no OD and those with no prior infection. OC mucus samples were evaluated for 13 anti-viral and inflammatory biomarkers. Cohorts were compared using analysis of variance (ANOVA) and Mann-Whitney tests with multi-comparison adjustment. Viral RNA was assessed through RT-PCR using the COVID-19 N2 primer. RESULTS: Thirty-five samples were collected (20 COVID persistent OD, 8 COVID no OD, and 7 non-COVID no OD). Significant differences in IFN-λ1 (p = 0.007) and IFN-γ (p = 0.006) expression in OC mucus were found across all three groups, with the highest cytokine concentrations corresponding to COVID OD. IFN-α2 levels were elevated in COVID OD versus no OD (p = 0.026). Mean IFN-γ levels were the highest in COVID OD, but there were higher levels found in COVID no OD compared to non-COVID no OD (p = 0.008). No difference was seen in IL6. No N2 gene expression was detected in all cohorts. CONCLUSION: IFN pathway cytokines were found elevated in the olfactory microenvironment of COVID-19 persistent OD compared to those with no OD and no prior history of COVID-19 infection.
- Published
- 2024
3. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD.
- Author
-
Badrani, Jana, Cavagnero, Kellen, Eastman, Jacqueline, Kim, Alex, Strohm, Allyssa, Deconde, Adam, Zuraw, Bruce, White, Andrew, Christiansen, Sandra, Doherty, Taylor, and Yan, Carol
- Subjects
15-HETE ,19 ,20-diHDPA ,AERD ,ILC2 ,asthma ,eicosanoid ,innate lymphoid cells ,lipidomic ,nasal polyps ,Humans ,Immunity ,Innate ,Lymphocytes ,Asthma ,Aspirin-Induced ,Hydroxyeicosatetraenoic Acids ,Cyclooxygenase Inhibitors ,Sinusitis ,Nasal Mucosa ,Prostaglandins ,Eicosanoids ,Aspirin ,Nasal Polyps - Abstract
BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is associated with high levels of cysteinyl leukotrienes, prostaglandin D2, and low levels of prostaglandin E2. Further, 15-hydroxyeicosatetraenoic acid (15-HETE) levels may have predictive value in therapeutic outcomes of aspirin desensitization. Accumulation of nasal group 2 innate lymphoid cells (ILC2s) has been demonstrated during COX-1 inhibition in AERD, although the relationships between tissue ILC2 accumulation, reaction symptom severity, and novel lipid biomarkers are unknown. OBJECTIVE: We sought to determine whether novel lipid mediators are predictive of nasal ILC2 accumulation and symptom scores during COX-1 inhibitor challenge in patients with AERD. METHODS: Blood and nasal scraping samples from patients with AERD were collected at baseline and COX-1 inhibitor reaction and then processed for flow cytometry for nasal ILC2s and serum for lipidomic analysis. RESULTS: Eight patients with AERD who were undergoing aspirin desensitization were recruited. Of the 161 eicosanoids tested, 42 serum mediators were detected. Baseline levels of 15-HETE were negatively correlated with the change in numbers of airway ILC2s (r = -0.6667; P = .0428). Docosahexaenoic acid epoxygenase metabolite 19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid (19,20-diHDPA) was positively correlated with both changes in airway ILC2s (r = 0.7143; P = .0305) and clinical symptom scores (r = 0.5000; P = .0081). CONCLUSION: Low levels of baseline 15-HETE predicted a greater accumulation of airway ILC2s in patients with AERD who were receiving COX-1 inhibition. Further, increases in the cytochrome P pathway metabolite 19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid (19,20-diHDPA) were associated with increased symptoms and nasal ILC2 accumulation. Future studies to assess how these mediators might control ILC2s may improve the understanding of AERD pathogenesis.
- Published
- 2023
4. Impact of Race, Ethnicity, and Socioeconomic Status on Nasopharyngeal Carcinoma Disease-Specific and Conditional Survival.
- Author
-
London, Ashley, Gallagher, Liam, Sharma, Rahul, Spielman, Daniel, Golub, Justin, Overdevest, Jonathan, Yan, Carol, DeConde, Adam, and Gudis, David
- Subjects
health outcomes ,nasopharyngeal carcinoma ,racial disparity ,socioeconomic status - Abstract
Introduction Race, ethnicity, and socioeconomic status (SES) are complex, interconnected social determinants of health outcomes. This study uses multivariable analysis on a combination of large national datasets to examine the effects of these factors on 5-year disease-specific survival (DSS) and conditional DSS (CDSS) for nasopharyngeal carcinoma (NPC). Methods A retrospective study of adults with NPC between 2000 and 2017 from the Surveillance, Epidemiology, End Results (SEER) registry was performed, using the National Cancer Institute Yost Index, a census tract-level composite score of SES to categorize patients. Kaplan-Meier analysis and Coxs regression for DSS and CDSS were stratified by SES. Logistic regression was conducted to identify risk factors for advanced cancer stage at time of diagnosis and receiving multimodal therapy. Results Our analysis included 5,632 patients. DSS was significantly associated with race and SES ( p
- Published
- 2022
5. Clinical factors associated with lower health scores in COVID‐19–related persistent olfactory dysfunction
- Author
-
Said, Mena, Luong, Thanh, Jang, Sophie S, Davis, Morgan E, DeConde, Adam S, and Yan, Carol H
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Good Health and Well Being ,COVID-19 ,COVID-19 Testing ,Female ,Humans ,Male ,Olfaction Disorders ,Quality of Life ,Smell ,health utility values ,parosmia ,persistent olfactory dysfunction ,quality of life ,Immunology ,Clinical sciences - Abstract
BackgroundPatients with persistent COVID-19 olfactory dysfunction (OD) commonly report parosmia. Understanding the impact of COVID-19 OD and parosmia is critical to prioritizing research and interventions. In this study we investigate the impact of parosmia and other clinical and disease characteristics on health state utility values (HUVs) for those with persistent COVID-19 OD.MethodsPatients with a history of COVID-19 diagnosis and persistent OD were recruited from a tertiary medical center and a social media support forum for chemosensory dysfunction. Clinical characteristics and disease-specific symptoms were obtained along with self-reported history of smell function and presence of parosmia. HUVs were calculated using indirect (EuroQol 5-Dimension [EQ-5D]) and direct (VAS) measures.ResultsOur study included 286 subjects (75.52% women) with persistent COVID-19-related OD. Results (mean ± standard deviation) of HUVs based on EQ-5D and VAS were 0.81 ± 0.14 and 0.73 ± 0.21, respectively. Mean self-reported smell function (on a 0-10 scale) was 9.67 ± 1.25 pre-COVID-19, 0.93 ± 2.34 at diagnosis, and 3.39 ± 2.32 at most current assessment. A total of 89.16% of the subjects reported parosmia and 24.13% sought medical care for anosmia. Seeing an MD for OD (p
- Published
- 2022
6. Impact of COVID-19 versus chronic rhinosinusitis/rhinitis associated olfactory dysfunction on health utility and quality of life.
- Author
-
Luong, Thanh, Jang, Sophie, Said, Mena, DeConde, Adam, and Yan, Carol
- Subjects
COVID‐19 ,chronic rhinosinusitis ,health utility values ,olfactory dysfunction ,quality of life - Abstract
BACKGROUND: Olfactory dysfunction (OD) is associated with both post-viral and inflammatory etiologies such as COVID-19 and chronic rhinosinusitis/rhinitis (CRS/R) respectively, to result in reduced quality of life (QoL). However, the former typically induces a sudden-onset OD while the latter has a gradual presentation. This study aims to establish and compare health utility values (HUVs) and olfactory-specific QoL measurements between patients with COVID-19 and CRS/R related OD. METHODS: This prospective study surveyed COVID-19 and CRS/R patients with self-reported OD using HUV assessments (EuroQol-visual analog scale [EQ-VAS], EuroQol-5 dimension [EQ-5D], time trade-off [TTO]) and olfactory and sinonasal QoL measures (questionnaire of olfactory disorders -negative and positive statements [QOD-NS + PS] and sino-nasal outcome test [SNOT-22]). A subgroup of subjects completed objective olfactory testing. Intergroup mean scores were compared using Mann-Whitney U tests. RESULTS: One hundred eleven subjects were enrolled: mean age ± SD (43.0 ± 15.4 years), 55.9% female. CRS/R was associated with lower HUVs as measured by EQ-VAS (CRS/R: 0.67 ± 0.18 vs. COVID-19: 0.74 ± 0.19, p = .03) and worse SNOT-22 scores in both overall (CRS/R: 49.03 ± 21.04 vs. COVID-19: 27.58 ± 18.45, p
- Published
- 2022
7. Immunohistochemical and qPCR Detection of SARS-CoV-2 in the Human Middle Ear Versus the Nasal Cavity: Case Series
- Author
-
Kurabi, Arwa, Pak, Kwang, DeConde, Adam S, Ryan, Allen F, and Yan, Carol H
- Subjects
Infectious Diseases ,Otitis Media ,Clinical Research ,Lung ,Ear ,Infection ,Angiotensin-Converting Enzyme 2 ,COVID-19 ,Ear ,Middle ,Humans ,Nasal Cavity ,SARS-CoV-2 ,Coronavirus ,Middle ear ,Nasal cavity ,qPCR ,Immunohistochemistry ,Clinical Sciences ,Dentistry - Abstract
Viral infections have already been implicated with otitis media and sudden sensorineural hearing loss. However, the pathophysiology of COVID-19 as it relates to otologic disorders is not well-defined. With the spread of SARS-CoV-2, it is important to evaluate its colonization of middle ear mucosa. Middle ear and nasal tissue samples for quantitative RT-PCR and histologic evaluations were obtained from post-mortem COVID-19 patients and non-diseased control patients. Here we present evidence that SARS-CoV-2 colonizes the middle ear epithelium and co-localizes with the primary viral receptor, angiotensin-converting enzyme 2 (ACE2). Both middle ear and nasal epithelial cells show relatively high expression of ACE2, required for SARS-CoV-2 entry. The epithelial cell adhesion molecule (EpCAM) was use as a biomarker of epithelia. Furthermore, we found that the viral load in the middle ear is lower than that present in the nasal cavity.
- Published
- 2022
8. Assessment of patient recognition of coronavirus disease 2019 (COVID-19)-associated olfactory loss and recovery: a longitudinal study.
- Author
-
Prajapati, Divya, Shahrvini, Bita, Said, Mena, Srinivas, Shanmukha, DeConde, Adam, and Yan, Carol
- Subjects
BSIT ,COVID-19 ,disease screening ,psychophysical testing ,smell loss ,COVID-19 ,Humans ,Longitudinal Studies ,Olfaction Disorders ,Prospective Studies ,SARS-CoV-2 ,Smell - Abstract
BACKGROUND: The clinical course of coronavirus disease 2019 (COVID-19) olfactory dysfunction remains poorly characterized, often limited by self-reported measures. Given the logistical challenges of psychophysical testing, understanding the longitudinal relationship between self-reported and quantitative measures can help accurately identify patients with persistent olfactory dysfunction. This study aimed to longitudinally correlate measured and subjective olfactory function in COVID-19 subjects. METHODS: A prospective, longitudinal study evaluating subjective and measured olfaction was conducted on ambulatory COVID-19 subjects. Olfaction scores were obtained using a visual analogue scale (VAS) (0 = anosmia, 10 = normosmia) and the validated 12-item Brief Smell Identification Test (BSIT). Weekly testing was performed until recovery (BSIT ≥ 9/12 and/or VAS = 10/10) or study completion. RESULTS: Eighty-six polymerase chain reaction (PCR)-positive COVID-19 subjects were recruited ≤3 days from diagnosis and 52 completed longitudinal testing. Among those with self-reported smell loss at recruitment, similar levels (75.8%) of objective (BSIT ≥ 9/12) and subjective recovery were obtained using a VAS cutoff ≥8, yet only 30.3% reported complete subjective recovery (VAS = 10). Median times to objective and complete subjective olfactory recovery were 12 ± 2.3 and 24 ± 3.5 days, respectively. Although both measures showed chemosensory improvement, the distributions of objective and full subjective olfactory recovery differed significantly (log rank test χ2 = 6.46, degrees of freedom [df] = 1, p = 0.011). Overall correlation between BSIT and VAS scores was moderate to strong across longitudinal follow-up (rs = 0.41-0.65). CONCLUSION: Self-reported and psychophysically measured COVID-19 olfactory dysfunction improve at similar levels and are moderately correlated longitudinally, yet there is a significant delay in complete subjective recovery. Psychophysical testing in conjunction with qualitative assessments may be considered for counseling and follow-up of patients with COVID-19 smell loss.
- Published
- 2021
9. Determinants of SARS-CoV-2 entry and replication in airway mucosal tissue and susceptibility in smokers
- Author
-
Nakayama, Tsuguhisa, Lee, Ivan T, Jiang, Sizun, Matter, Matthias S, Yan, Carol H, Overdevest, Jonathan B, Wu, Chien-Ting, Goltsev, Yury, Shih, Liang-Chun, Liao, Chun-Kang, Zhu, Bokai, Bai, Yunhao, Lidsky, Peter, Xiao, Yinghong, Zarabanda, David, Yang, Angela, Easwaran, Meena, Schürch, Christian M, Chu, Pauline, Chen, Han, Stalder, Anna K, McIlwain, David R, Borchard, Nicole A, Gall, Phillip A, Dholakia, Sachi S, Le, Wei, Xu, Le, Tai, Chih-Jaan, Yeh, Te-Huei, Erickson-Direnzo, Elizabeth, Duran, Jason M, Mertz, Kirsten D, Hwang, Peter H, Haslbauer, Jasmin D, Jackson, Peter K, Menter, Thomas, Andino, Raul, Canoll, Peter D, DeConde, Adam S, Patel, Zara M, Tzankov, Alexandar, Nolan, Garry P, and Nayak, Jayakar V
- Subjects
Dental/Oral and Craniofacial Disease ,Tobacco ,Prevention ,Biodefense ,Pneumonia & Influenza ,Emerging Infectious Diseases ,Infectious Diseases ,Pneumonia ,Tobacco Smoke and Health ,Clinical Research ,Vaccine Related ,Lung ,2.1 Biological and endogenous factors ,Aetiology ,2.2 Factors relating to the physical environment ,Infection ,Respiratory ,Good Health and Well Being ,Aged ,Aged ,80 and over ,Angiotensin-Converting Enzyme 2 ,COVID-19 ,Female ,Gene Expression Regulation ,Humans ,Male ,Middle Aged ,Nasal Cavity ,Respiratory Mucosa ,SARS-CoV-2 ,Serine Endopeptidases ,Smokers ,Trachea ,Viral Tropism ,ACE2 ,IFN-β1 ,TMPRSS2 ,ciliated epithelial cell ,nasal cavity ,smoking ,trachea ,upper airway - Abstract
Understanding viral tropism is an essential step toward reducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, decreasing mortality from coronavirus disease 2019 (COVID-19) and limiting opportunities for mutant strains to arise. Currently, little is known about the extent to which distinct tissue sites in the human head and neck region and proximal respiratory tract selectively permit SARS-CoV-2 infection and replication. In this translational study, we discover key variabilities in expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), essential SARS-CoV-2 entry factors, among the mucosal tissues of the human proximal airways. We show that SARS-CoV-2 infection is present in all examined head and neck tissues, with a notable tropism for the nasal cavity and tracheal mucosa. Finally, we uncover an association between smoking and higher SARS-CoV-2 viral infection in the human proximal airway, which may explain the increased susceptibility of smokers to developing severe COVID-19. This is at least partially explained by differences in interferon (IFN)-β1 levels between smokers and non-smokers.
- Published
- 2021
10. Pediatric Nasal Chondromesenchymal Tumors: Case Report and Review of the Literature
- Author
-
Schaerer, Daniel, Nation, Javan, Rennert, Robert C, DeConde, Adam, and Levy, Michael L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Brain Disorders ,Pediatric ,Rare Diseases ,Brain Cancer ,Clinical Research ,Dental/Oral and Craniofacial Disease ,Cancer ,Biopsy ,Brain Neoplasms ,Child ,Endoscopy ,Humans ,Infant ,Magnetic Resonance Imaging ,Male ,Neurosurgical Procedures ,Chondromesenchymal ,Hamartoma ,Nasal tumor ,Pediatric sinus surgery ,Pediatric neurosurgery ,Pediatric skull base surgery ,Neurosciences ,Paediatrics and Reproductive Medicine ,Neurology & Neurosurgery ,Clinical sciences ,Paediatrics - Abstract
IntroductionNasal chondromesenchymal tumors (NCMT) are rare benign neoplasms that usually present in children
- Published
- 2021
11. Persistent Smell Loss Following Undetectable SARS-CoV-2
- Author
-
Yan, Carol H, Prajapati, Divya P, Ritter, Michele L, and DeConde, Adam S
- Subjects
Dental/Oral and Craniofacial Disease ,Neurosciences ,Clinical Research ,Betacoronavirus ,COVID-19 ,Coronavirus Infections ,Cross-Sectional Studies ,Humans ,Incidence ,Olfaction Disorders ,Pandemics ,Pneumonia ,Viral ,Prevalence ,SARS-CoV-2 ,Smell ,United States ,smell loss ,health care workers ,health care policy ,Clinical Sciences ,Otorhinolaryngology - Abstract
The association of smell and taste loss with COVID-19 has been well demonstrated with high prevalence rates. In certain cases, chemosensory loss may be the only symptom of COVID-19 and may linger while other symptoms have resolved. The significance of persistent smell and taste loss and its relationship to ongoing viral shedding has yet to be investigated. In this cross-sectional study, of the 316 laboratory test-confirmed COVID-19 cases at our institution, 46 had subsequent test-based confirmation of viral clearance with 2 consecutive negative RT-PCR test results (reverse transcriptase polymerase chain reaction). Olfactory dysfunction was reported by 50% of the patients (23 of 46), with 78% (18 of 23) having subjective persistent smell loss despite negative RT-PCR test results. These preliminary data demonstrate the persistence of self-reported smell loss despite otherwise clinical resolution and undetectable nasal viral RNA.
- Published
- 2020
12. In Reply: Navigating personal risk in rhinologic surgery during the COVID‐19 pandemic
- Author
-
DeConde, Adam S, Yan, Carol H, and DeConde, Robert P
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,COVID-19 ,Humans ,Negative Results ,Otolaryngology ,Pandemics ,SARS-CoV-2 ,Clinical sciences - Published
- 2020
13. Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptoms
- Author
-
Yan, Carol H, Faraji, Farhoud, Prajapati, Divya P, Boone, Christine E, and DeConde, Adam S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Emerging Infectious Diseases ,Clinical Research ,Prevention ,Pneumonia & Influenza ,Neurosciences ,Infection ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Betacoronavirus ,COVID-19 ,Coronavirus Infections ,Cross-Sectional Studies ,Female ,Humans ,Male ,Middle Aged ,Olfaction Disorders ,Pandemics ,Pneumonia ,Viral ,Prevalence ,SARS-CoV-2 ,Taste Disorders ,Young Adult ,smell loss ,taste loss ,patient outcomes ,Immunology ,Clinical sciences - Abstract
BackgroundRapid spread of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and concern for viral transmission by ambulatory patients with minimal to no symptoms underline the importance of identifying early or subclinical symptoms of coronavirus disease 2019 (COVID-19) infection. Two such candidate symptoms include anecdotally reported loss of smell and taste. Understanding the timing and association of smell/taste loss in COVID-19 may help facilitate screening and early isolation of cases.MethodsA single-institution, cross-sectional study evaluating patient-reported symptoms with a focus on smell and taste was conducted using an internet-based platform on adult subjects who underwent testing for COVID-19. Logistic regression was employed to identify symptoms associated with COVID-19 positivity.ResultsA total of 1480 patients with influenza-like symptoms underwent COVID-19 testing between March 3, 2020, and March 29, 2020. Our study captured 59 of 102 (58%) COVID-19-positive patients and 203 of 1378 (15%) COVID-19-negative patients. Smell and taste loss were reported in 68% (40/59) and 71% (42/59) of COVID-19-positive subjects, respectively, compared to 16% (33/203) and 17% (35/203) of COVID-19-negative patients (p < 0.001). Smell and taste impairment were independently and strongly associated with COVID-19 positivity (anosmia: adjusted odds ratio [aOR] 10.9; 95% CI, 5.08-23.5; ageusia: aOR 10.2; 95% CI, 4.74-22.1), whereas sore throat was associated with COVID-19 negativity (aOR 0.23; 95% CI, 0.11-0.50). Of patients who reported COVID-19-associated loss of smell, 74% (28/38) reported resolution of anosmia with clinical resolution of illness.ConclusionIn ambulatory individuals with influenza-like symptoms, chemosensory dysfunction was strongly associated with COVID-19 infection and should be considered when screening symptoms. Most will recover chemosensory function within weeks, paralleling resolution of other disease-related symptoms.
- Published
- 2020
14. Self‐reported olfactory loss associates with outpatient clinical course in COVID‐19
- Author
-
Yan, Carol H, Faraji, Farhoud, Prajapati, Divya P, Ostrander, Benjamin T, and DeConde, Adam S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Neurosciences ,Lung ,Clinical Research ,Good Health and Well Being ,Adult ,Aged ,Betacoronavirus ,COVID-19 ,Coronavirus Infections ,Disease Progression ,Female ,Hospitalization ,Humans ,Male ,Middle Aged ,Olfaction Disorders ,Pandemics ,Pneumonia ,Viral ,Retrospective Studies ,Risk Factors ,SARS-CoV-2 ,Self Report ,smell loss ,taste loss ,patient outcomes ,admission ,hospitalization ,Immunology ,Clinical sciences - Abstract
BackgroundRapid spread of the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus has left many health systems around the world overwhelmed, forcing triaging of scarce medical resources. Identifying indicators of hospital admission for coronavirus disease 2019 (COVID-19) patients early in the disease course could aid the efficient allocation of medical interventions. Self-reported olfactory impairment has recently been recognized as a hallmark of COVID-19 and may be an important predictor of clinical outcome.MethodsA retrospective review of all patients presenting to a San Diego Hospital system with laboratory-confirmed positive COVID-19 infection was conducted with evaluation of olfactory and gustatory function and clinical disease course. Univariable and multivariable logistic regression were performed to identify risk factors for hospital admission and anosmia.ResultsA total of 169 patients tested positive for COVID-19 disease between March 3 and April 8, 2020. Olfactory and gustatory data were obtained for 128 (75.7%) of 169 subjects, of which 26 (20.1%) of 128 required hospitalization. Admission for COVID-19 was associated with intact sense of smell and taste, increased age, diabetes, and subjective and objective parameters associated with respiratory failure. On adjusted analysis, anosmia was strongly and independently associated with outpatient care (adjusted odds ratio [aOR] 0.09; 95% CI, 0.01-0.74), whereas positive findings of pulmonary infiltrates and/or pleural effusion on chest radiograph (aOR 8.01; 95% CI, 1.12-57.49) was strongly and independently associated with admission.ConclusionNormosmia is an independent predictor of admission in COVID-19 cases. Smell loss in COVID-19 may be associated with a milder clinical course.
- Published
- 2020
15. Reply to: Self‐reported olfactory loss in COVID‐19: is it really a favorable prognostic factor?
- Author
-
Yan, Carol H, Faraji, Farhoud, and DeConde, Adam S
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Immunology ,Betacoronavirus ,COVID-19 ,Coronavirus Infections ,Humans ,Pandemics ,Pneumonia ,Viral ,Prognosis ,SARS-CoV-2 ,Self Report ,Clinical sciences - Published
- 2020
16. Pediatric Endoscopic Endonasal Approaches for Skull Base Lesions in the Very Young: Is It Safe and Effective?
- Author
-
Nation, Javan, Schupper, Alexander J, Deconde, Adam, and Levy, Michael
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Neurosciences ,Brain Disorders ,Pediatric Research Initiative ,Rare Diseases ,Pediatric ,Cancer ,pediatric endoscopic endonasal approach ,expanded endoscopic endonasal approach ,EEA ,pediatric skull base surgery ,surgical complications ,Neurology & Neurosurgery ,Dentistry - Abstract
Introduction The fully endoscopic expanded endonasal approach (EEA) has been shown to be safe and efficacious in pediatric patients. However, in the very young patient (ages six and under), the anatomical challenge of working through a small nasal corridor is problematic. The ability to repair the skull base and use a nasoseptal flap (NSF) has also been called into question. Here, we review skull base resections using EEA in patients aged 6 years and younger. Methods A retrospective chart review was conducted on pediatric patients age 6 years and younger who underwent EEA skull base resections over a 3-year period (June 2014 through June 2017). Results Eight children aged 6 and under with seven tumor pathologies underwent an EEA for the resection of their skull base tumors, with a mean follow-up of 1.45 years. Only chordoma cases required multiple-staged resections. There are no tumor recurrences to date. A high-flow intraoperative cerebrospinal fluid (CSF) leak was encountered in three cases, and there were no postoperative CSF leaks. CSF leaks were effectively repaired with NSFs. One patient suffered from postoperative hypopituitarism, one patient experienced recurrent epistaxis secondary to turbinate destruction by the tumor, and one patient expired 8 months postresection secondary to metastatic disease. Conclusion In our case series, EEA for skull base tumors in children aged 6 and under was a safe and effective surgical approach. Skull base defects are able to be effectively addressed with typical repairs including NSFs. Larger studies are warranted to further investigate this technique in this pediatric population.
- Published
- 2018
17. Multifocal Inflammatory Pseudotumor of the Temporal Bone, Maxillary Sinus, and Orbit
- Author
-
Sakano, Hitomi, Shih, Cheng-Ping, Jafari, Aria, DeConde, Adam, and Harris, Jeffrey P
- Subjects
Allied Health and Rehabilitation Science ,Biomedical and Clinical Sciences ,Clinical Sciences ,Health Sciences ,Rare Diseases ,Bone Diseases ,Combined Modality Therapy ,Glucocorticoids ,Granuloma ,Plasma Cell ,Humans ,Immunologic Factors ,Male ,Maxillary Sinus ,Middle Aged ,Orbit ,Orthopedic Procedures ,Prednisone ,Radiotherapy ,Rituximab ,Temporal Bone ,Treatment Outcome ,Fibrous xanthoma ,Histiocytoma complex ,Inflammatory myofibroblastic tumor ,Inflammatory myofibrohistiocytic proliferation ,Inflammatory pseudotumor ,Plasma cell granuloma ,Xanthomatous pseudotumor ,Zoology ,Public Health and Health Services ,Otorhinolaryngology ,Clinical sciences ,Allied health and rehabilitation science - Abstract
ObjectiveThis is the first report of multifocal inflammatory pseudotumor (IPT) involving the temporal bone, orbit and paranasal sinus, and the use of rituximab as adjunctive therapy in multifocal temporal bone IPT.PatientWe describe a 46-year-old man with orbital and maxillary sinus IPT, whose disease progressed despite radiation and steroid burst. He then developed contralateral mastoid disease, otalgia, aural fullness, and hearing loss.InterventionHe was initiated on rituximab and prednisone therapy. Mastoidectomy with near-total tumor removal was accomplished and histopathology confirmed IPT. A literature review was also performed.Main outcome measureTumor regression or recurrence.ResultDespite disease progression after radiation and steroids, his orbital, sinus, and mastoid disease improved after surgery, steroids, and rituximab. A review of four other previously reported cases of multifocal disease involving the temporal bone suggest that multifocal disease may be a more aggressive entity with higher recurrence rate compared with solitary disease. Although surgery and steroids are typically recommended, there is currently no consensus treatment recommendation.ConclusionsMultifocal IPT of the temporal bone is a rare but aggressive entity for which surgery and steroid combination therapy should be first line treatment. We suggest rituximab may be an effective adjunctive treatment particularly for recurrent disease or where systemic therapy may be favored.
- Published
- 2018
18. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
- Author
-
Wise, Sarah K, Lin, Sandra Y, Toskala, Elina, Orlandi, Richard R, Akdis, Cezmi A, Alt, Jeremiah A, Azar, Antoine, Baroody, Fuad M, Bachert, Claus, Canonica, G Walter, Chacko, Thomas, Cingi, Cemal, Ciprandi, Giorgio, Corey, Jacquelynne, Cox, Linda S, Creticos, Peter Socrates, Custovic, Adnan, Damask, Cecelia, DeConde, Adam, DelGaudio, John M, Ebert, Charles S, Eloy, Jean Anderson, Flanagan, Carrie E, Fokkens, Wytske J, Franzese, Christine, Gosepath, Jan, Halderman, Ashleigh, Hamilton, Robert G, Hoffman, Hans Jürgen, Hohlfeld, Jens M, Houser, Steven M, Hwang, Peter H, Incorvaia, Cristoforo, Jarvis, Deborah, Khalid, Ayesha N, Kilpeläinen, Maritta, Kingdom, Todd T, Krouse, Helene, Larenas-Linnemann, Desiree, Laury, Adrienne M, Lee, Stella E, Levy, Joshua M, Luong, Amber U, Marple, Bradley F, McCoul, Edward D, McMains, K Christopher, Melén, Erik, Mims, James W, Moscato, Gianna, Mullol, Joaquim, Nelson, Harold S, Patadia, Monica, Pawankar, Ruby, Pfaar, Oliver, Platt, Michael P, Reisacher, William, Rondón, Carmen, Rudmik, Luke, Ryan, Matthew, Sastre, Joaquin, Schlosser, Rodney J, Settipane, Russell A, Sharma, Hemant P, Sheikh, Aziz, Smith, Timothy L, Tantilipikorn, Pongsakorn, Tversky, Jody R, Veling, Maria C, Wang, De Yun, Westman, Marit, Wickman, Magnus, and Zacharek, Mark
- Subjects
Allergic Rhinitis (Hay Fever) ,Adrenal Cortex Hormones ,Allergens ,Biological Products ,Complementary Therapies ,Cytokines ,Diagnosis ,Differential ,Drug Therapy ,Combination ,Endoscopy ,Environmental Exposure ,Epidemiologic Methods ,Histamine Antagonists ,Humans ,Immunoglobulin E ,Microbiota ,Nasal Decongestants ,Occupational Diseases ,Physical Examination ,Probiotics ,Quality of Life ,Respiratory Mucosa ,Rhinitis ,Allergic ,Risk Factors ,Saline Solution ,Skin Tests ,Socioeconomic Factors ,allergen extract ,allergy ,allergen immunotherapy ,allergic rhinitis ,antihistamine ,asthma ,atopic dermatitis ,avoidance ,biologic ,cockroach ,conjunctivitis ,consensus ,corticosteroid ,cough ,cromolyn ,decongestant ,eosinophilic esophagitis ,environment ,epicutaneous immunotherapy ,epidemiology ,evidence-based medicine ,food allergy ,genetics ,house dust mite ,IgE ,immunoglobulin E ,immunotherapy ,inhalant allergy ,leukotriene ,microbiome ,occupational rhinitis ,omalizumab ,pathophysiology ,perennial ,pet dander ,pollen ,probiotic ,quality of life ,rhinitis ,rhinosinusitis ,risk factor ,saline ,seasonal ,sensitization ,sinusitis ,sleep ,socioeconomic ,specific IgE ,subcutaneous immunotherapy ,sublingual immunotherapy ,systematic review ,total IgE ,transcutaneous immunotherapy ,validated survey ,Immunology - Abstract
BackgroundCritical examination of the quality and validity of available allergic rhinitis (AR) literature is necessary to improve understanding and to appropriately translate this knowledge to clinical care of the AR patient. To evaluate the existing AR literature, international multidisciplinary experts with an interest in AR have produced the International Consensus statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR).MethodsUsing previously described methodology, specific topics were developed relating to AR. Each topic was assigned a literature review, evidence-based review (EBR), or evidence-based review with recommendations (EBRR) format as dictated by available evidence and purpose within the ICAR:AR document. Following iterative reviews of each topic, the ICAR:AR document was synthesized and reviewed by all authors for consensus.ResultsThe ICAR:AR document addresses over 100 individual topics related to AR, including diagnosis, pathophysiology, epidemiology, disease burden, risk factors for the development of AR, allergy testing modalities, treatment, and other conditions/comorbidities associated with AR.ConclusionThis critical review of the AR literature has identified several strengths; providers can be confident that treatment decisions are supported by rigorous studies. However, there are also substantial gaps in the AR literature. These knowledge gaps should be viewed as opportunities for improvement, as often the things that we teach and the medicine that we practice are not based on the best quality evidence. This document aims to highlight the strengths and weaknesses of the AR literature to identify areas for future AR research and improved understanding.
- Published
- 2018
19. Negative Sinus Biopsy Does Not Rule Out Orbital Invasive Fungal Sinusitis
- Author
-
Bernstein, Jeffrey D., primary, Lin, Grace Y., additional, Yan, Carol, additional, and DeConde, Adam, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Ahlström Emanuelsson, Cecilia, Ardusso, Ledit, Armstrong, Michael, Bardin, Philip, Barnes, Sara, Bergna, Miguel, Betz, Christian, Beule, Achim, Blotter, James, Bronescu, Valeriu, Brown, Matthew, Carrie, Sean, Chaker, Adam, Cho, Hyung-Ju, Corriveau, Marie-Noëlle, Courville, Timothy, Cuevas, Mandy, Damask, Cecelia, DeConde, Adam, Del Carpio, Jaime, De Salvo, María, Dhong, Hun-Jong, Durham, Stephen, Edin, Anton, Ehmer Jr, Dale, Elías, Pedro, Fatakia, Adil, Franzese, Christine, Gane, Simon, García, Gabriel, Gillman, Andrew, Groeger, Moritz, Harvey, Richard, Hellgren, Johan, Higgins, Thomas, Hobson, Jonathan, Jangard, Mattias, Janjua, Arif, Kara, Naveed, Karpischenko, Sergey, Kerwin, Edward, Khanova, Fatimat, Kilty, Shaun, Kim, Chang-Hoon, Kim, Seontae, Klimek, Ludger, LaForce, Craig, Leong, Samuel, Marple, Bradley, Mårtensson, Anders, Maspero, Jorge, Massey, Neil, Matz, Jonathan, McDuffie, Chad, Mella, Corina, Miller, Steven, Mirzabekyan, Ekaterina, Moss, Jonathan, Mumneh, Nayla, Nathan, Robert, Neagos, Adriana, Olze, Heidi, Ovchinnikov, Andrey, Ow, Randall, Polyakov, Dmitriy, Radeanu, Doinel, Rhee, Chae-Seo, Rojas, Ramón, Rosenbloom, Jeffrey, Ryazantsev, Sergei, Sader, Chady, Saez Scherbovsky, Pablo, Scadding, Guy, Schlosser, Rodney, Shah-Patel, Heena, Shealy, Ronald, Siddiqi, Ayesha, Silvers, Stacey, Singh, Narinder, Sommer, Doron, Soong, Weily, Sowerby, Leigh, Spafford, Peter, Stefan, Catalin, Sterling, Richard, Svistushkin, Valeriy, Talreja, Neetu, Tarasova, Galina, Tarpay, Martha, Tolcachier, Alberto, Toll, Karin Toll, van Schaik, Carolina, Webb, Luke, Wedner, H James, Wehbe, Luis, Whan Kim, Soo, Wollenberg, Barbara, Wright, Simon, Yakusevich, Vladimir, Yañez, Anahí, Yarin, Yury, Yen, David, Yeol Kim, Hyo, Han, Joseph K, Bachert, Claus, Fokkens, Wytske, Desrosiers, Martin, Wagenmann, Martin, Lee, Stella E, Smith, Steven G, Martin, Neil, Mayer, Bhabita, Yancey, Steven W, Sousa, Ana R, Chan, Robert, and Hopkins, Claire
- Published
- 2021
- Full Text
- View/download PDF
21. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease
- Author
-
Eastman, Jacqueline J, Cavagnero, Kellen J, Deconde, Adam S, Kim, Alex S, Karta, Maya R, Broide, David H, Zuraw, Bruce L, White, Andrew A, Christiansen, Sandra C, and Doherty, Taylor A
- Subjects
Biomedical and Clinical Sciences ,Immunology ,Clinical Research ,2.1 Biological and endogenous factors ,Aetiology ,Inflammatory and immune system ,Adult ,Aged ,Asthma ,Aspirin-Induced ,Cell Count ,Cyclooxygenase Inhibitors ,Desensitization ,Immunologic ,Dinoprost ,Female ,Humans ,Ketorolac ,Leukotriene E4 ,Lymphocytes ,Male ,Middle Aged ,Nasal Mucosa ,Group 2 innate lymphoid cells ,aspirin-exacerbated respiratory disease ,Allergy - Abstract
BackgroundAspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD.ObjectiveWe sought to determine whether ILC2 numbers change in peripheral blood and the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD.MethodsBlood and nasal scrapings were collected at baseline, during reactions, and after completion of ketorolac/aspirin challenge/desensitization in 12 patients with AERD. ILC2s and eosinophils were quantitated by means of flow cytometry. Urine was also collected, and quantification of PGD2 metabolite and leukotriene E4 levels was done by using ELISA. Baseline and nonsteroidal anti-inflammatory drug reaction clinical data were correlated with cell changes.ResultsILC2 numbers significantly increased in nasal mucosal samples and decreased in blood at the time of COX-1 inhibitor reactions in 12 patients with AERD. These changes were not observed in 2 patients without AERD. Furthermore, eosinophil numbers decreased in blood concurrently with significant increases in urinary PGD2 metabolite and leukotriene E4 levels. The magnitude of increases in nasal mucosal ILC2 numbers positively correlated with maximum symptom scores during challenges. Furthermore, blood ILC2 numbers during the reaction correlated with time for the reaction to resolve, possibly reflecting reaction severity.ConclusionsILC2s are recruited to the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD, correlating with enhanced production of prostaglandins and leukotrienes.
- Published
- 2017
22. Improvements in psychological dysfunction after endoscopic sinus surgery for patients with chronic rhinosinusitis
- Author
-
Levy, Joshua M, Mace, Jess C, DeConde, Adam S, Steele, Toby O, and Smith, Timothy L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Neurosciences ,Brain Disorders ,Depression ,Behavioral and Social Science ,Mind and Body ,Mental Health ,Clinical Research ,Mental health ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Chronic Disease ,Endoscopy ,Female ,Humans ,Male ,Middle Aged ,Paranasal Sinuses ,Postoperative Period ,Quality of Life ,Rhinitis ,Sinusitis ,Treatment Outcome ,Young Adult ,sinusitis ,psychology ,quality of life ,patient outcome assessment ,chronic rhinosinusitis ,endoscopic sinus surgery ,Immunology ,Clinical sciences - Abstract
BackgroundPsychological dysfunction is highly prevalent among patients with chronic rhinosinusitis (CRS). Previous study has identified various measures of anxiety and depression as predictors of quality-of-life outcomes following endoscopic sinus surgery (ESS). Psychological dysfunction scores, as measured by the 22-item Sino-Nasal Outcome Test (SNOT-22), have been found to influence treatment decision making in CRS. This study aims to further elucidate improvement in discrete psychological symptoms following ESS for CRS.MethodsAdult patients with medically recalcitrant CRS electing to undergo ESS were prospectively enrolled into a multi-institutional, observational cohort. Psychological-related symptom severity and postoperative outcomes were assessed using psychological domain items of the SNOT-22, including subgroup analysis of patients with and without comorbid depression.ResultsA total of 374 participants met inclusion criteria and were followed postoperatively for a mean ± standard deviation (SD) of 14.6 ± 5.0 months. Total mean psychological domain scores improved from 15.9 ± 8.2 to 8.5 ± 8.4 (p < 0.001). Significant relative mean improvements were reported in "waking up tired" (23%; p < 0.001), "fatigue" (25%; p < 0.001), "reduced productivity" (28%; p < 0.001), "reduced concentration" (27%; p < 0.001), " frustrated/restless/irritable" (27%; p < 0.001), "sad" (15%; p < 0.001), and "embarrassed" (8%; p < 0.001) scores. A total of 64% to 66% of participants reported improvement in "reduced productivity," "waking up tired," "fatigue," and "frustrated/restless/irritable," compared to 46% and 38% reporting improvement in "sad" and "embarrassed," respectively.ConclusionPatients with CRS report significant improvement in common mental health-related symptoms following ESS. Despite these improvements, some degree of persistent postoperative psychological dysfunction was reported. Further study is necessary to determine which factors are associated with persistent psychological dysfunction after ESS in order to optimize treatment outcomes.
- Published
- 2016
23. Patient‐centered decision making: the role of the baseline SNOT‐22 in predicting outcomes for medical management of chronic rhinosinusitis
- Author
-
Steele, Toby O, Rudmik, Luke, Mace, Jess C, DeConde, Adam S, Alt, Jeremiah A, and Smith, Timothy L
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Patient Safety ,Adult ,Aged ,Chronic Disease ,Decision Making ,Endoscopy ,Female ,Humans ,Male ,Middle Aged ,Patient Participation ,Prospective Studies ,Quality of Life ,Rhinitis ,Severity of Illness Index ,Sinusitis ,Treatment Outcome ,sinusitis ,outcome assessment ,patient outcome assessment ,case-control studies ,medical therapy management ,Immunology ,Clinical sciences - Abstract
BackgroundFor patients with chronic rhinosinusitis (CRS), the decision to elect continued medical management vs surgery is complex and involves tradeoffs between benefits, risks, and overall effectiveness of each therapy. The purpose of this study is to investigate whether baseline disease-specific quality of life (QOL) can assist in predicting outcomes in patients with refractory CRS who elect continued medical management.MethodsCRS patients electing medical management were enrolled in a prospective, multi-institutional cohort study. Patients were stratified into pretreatment 22-item Sino-Nasal Outcome Test (SNOT-22) subgroups based on 10-point score increments (eg, 10 to 19, 20 to 29, 30 to 39, etc.) to capture potential outcome differences by baseline SNOT-22 disease burden. The proportion of patients achieving minimal clinically important difference (MCID≥9 points) and relative improvement (%) for each score category were calculated.ResultsSeventy-five CRS patients with a mean ± standard deviation pretreatment SNOT-22 score of 45.2 ± 16.6 were followed for a mean of 14.9 months. The majority of participants electing medical therapy failed to improve 1 MCID (57%) with a mean relative score improvement of 16%. Overall, 37% of patients maintained baseline SNOT-22 QOL status, whereas 20% of patients deteriorated >1 MCID. When treatment crossover patients (to endoscopic sinus surgery [ESS]) were included (n = 117), approximately 1 in 4 (27%) patients achieved an MCID.ConclusionResults from this study suggest that the majority of CRS patients electing ongoing medical management with low baseline disease-specific QOL impairment maintain stable QOL with continued medical management. Furthermore, of CRS patients electing ongoing medical therapy, approximately 1 in 4 patients achieved MCID, whereas 1 in 5 experienced deterioration by >1 MCID.
- Published
- 2016
24. Patients electing medical vs surgical treatment: emotional domain of the Rhinosinusitis Disability Index associates with treatment selection
- Author
-
Orb, Quinn, Mace, Jess C, DeConde, Adam S, Steele, Toby O, Cox, Steve T, Smith, Timothy L, and Alt, Jeremiah A
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Research ,Adult ,Aged ,Chronic Disease ,Drug Therapy ,Emotions ,Endoscopy ,Female ,Humans ,Male ,Middle Aged ,Prospective Studies ,Rhinitis ,Rhinoplasty ,Severity of Illness Index ,Sinusitis ,sinusitis ,quality of life ,patient selection ,endoscopy ,questionnaires ,Immunology ,Clinical sciences - Abstract
BackgroundThe Rhinosinusitis Disability Index (RSDI) consists of multiple subdomains shown to be useful in studying chronic rhinosinusitis (CRS). The objective of this study was to determine if RSDI subdomain scores are associated with selection of treatment modality (endoscopic sinus surgery [ESS] or continued medical management [CMM]) in subjects with CRS.MethodsPatients with CRS were prospectively enrolled into a multi-institutional cohort study. Following an initial period of medical management, patients elected to undergo treatment with either ESS or CMM. Baseline RSDI total and subdomain scores were compared between patients electing different treatment modalities.ResultsA total of 684 subjects were enrolled with 122 (17.8%) electing CMM and 562 (82.2%) electing ESS. When compared to patients undergoing CMM, patients electing ESS exhibited significantly higher mean baseline RSDI total scores (mean ± standard deviation [SD]: 48.1 ± 24.9 vs 40.1 ± 24.1; p = 0.001) and subdomain scores (emotional: 13.2 ± 9.1 vs 10.4 ± 8.3; p = 0.001; functional: 15.3 ± 8.9 vs 12.6 ± 8.4; p = 0.002; and physical: 19.6 ± 9.3 vs 17.1 ± 9.6; p = 0.007). Emotional subdomain scores were found to be the most associated with choice of treatment modality.ConclusionPatients with CRS electing ESS had worse baseline RSDI total and subdomain scores compared to those electing CMM. Although both rhinologic and nonrhinologic symptoms contributed to the selection of treatment modality, emotional symptoms appeared to exhibit the greatest influence on patient-centered treatment decisions.
- Published
- 2016
25. Does comorbid obesity impact quality of life outcomes in patients undergoing endoscopic sinus surgery?
- Author
-
Steele, Toby O, Mace, Jess C, DeConde, Adam S, Xiao, Christopher C, Storck, Kristina A, Gudis, David A, Schlosser, Rodney J, Soler, Zachary M, and Smith, Timothy L
- Subjects
Health Services ,Clinical Research ,Clinical Trials and Supportive Activities ,Obesity ,Nutrition ,7.1 Individual care needs ,Management of diseases and conditions ,Oral and gastrointestinal ,Metabolic and endocrine ,Adult ,Aged ,Body Mass Index ,Chronic Disease ,Comorbidity ,Endoscopy ,Female ,Follow-Up Studies ,Humans ,Male ,Middle Aged ,Paranasal Sinuses ,Prevalence ,Prospective Studies ,Quality of Life ,Rhinitis ,Sinusitis ,Treatment Outcome ,United States ,sinusitis ,endoscopy ,chronic disease ,quality of life ,obesity ,overweight ,body mass index ,Immunology - Abstract
BackgroundBoth obesity and chronic rhinosinusitis (CRS) are characterized by inflammation. Furthermore, both disease processes are independently associated with decreases in quality-of-life (QOL). We sought to investigate the role of comorbid obesity in QOL outcomes in CRS patients undergoing endoscopic sinus surgery (ESS).MethodsAdult patients with medically refractory CRS (n = 241) were prospectively enrolled into a multi-institutional treatment outcomes investigation. Body mass index (BMI) calculations were used to differentiate patient weight groups (normal weight: 18.5 to 24.9, overweight: 25.0 to 29.9; and obese: ≥30.0). Preoperative and postoperative QOL (Rhinosinusitis Disability Index [RSDI] and the 22-item Sino-Nasal Outcome Test [SNOT-22]) were evaluated compared across BMI groups and obesity subclasses.ResultsThe prevalence of comorbid obesity was 41% (n = 99). Higher prevalence of comorbid disease was found across increasing BMI groups including diabetes mellitus, asthma, and depression. No significant differences were found in mean preoperative QOL measures between any BMI groups. Significant improvement between preoperative and postoperative QOL mean scores (p ≤ 0.050) was found for all BMI groups. Despite no significant difference in mean QOL improvement between BMI groups (p ≥ 0.142), overweight and obese patients reported reduced relative mean percentage (%) improvement compared to normal weight participants on the RSDI total score (33% and 37% vs 55%, respectively) and SNOT-22 total score (29% and 40% vs 48%, respectively).ConclusionPatients with comorbid obesity experience significant improvement in average QOL gains following ESS though the percentage of relative improvement in QOL may be decreased in patients with comorbid obesity and CRS as compared to those without.
- Published
- 2015
26. CSF leak after endoscopic skull base surgery in children: A single institution experience
- Author
-
Nation, Javan, Schupper, Alexander J., Deconde, Adam, and Levy, Michael
- Published
- 2019
- Full Text
- View/download PDF
27. Pro‐inflammatory markers associated with COVID‐19‐related persistent olfactory dysfunction
- Author
-
Jang, Sophie S., primary, Pak, Kwang S., additional, Strom, Allyssa, additional, Gomez, Leslie, additional, Kim, Kyubo, additional, Doherty, Taylor A., additional, DeConde, Adam S., additional, Ryan, Allen F., additional, and Yan, Carol H., additional
- Published
- 2023
- Full Text
- View/download PDF
28. An updated assessment of morbidity and mortality following skull base surgical approaches
- Author
-
Burton, Brittany N., Hu, Jenny Q., Jafari, Aria, Urman, Richard D., Dunn, Ian F., Bi, W. Linda, DeConde, Adam S., and Gabriel, Rodney A.
- Published
- 2018
- Full Text
- View/download PDF
29. Bilateral Inferior Turbinate Flaps for Salvage Reconstruction after Proton Beam Radiotherapy for Clival Chordoma
- Author
-
Crawford, Kayva L., additional, Saripella, Megana, additional, DeConde, Adam S., additional, and Beaumont, Thomas L., additional
- Published
- 2023
- Full Text
- View/download PDF
30. Classification of Chronic Rhinosinusitis—Working Toward Personalized Diagnosis
- Author
-
DeConde, Adam S. and Smith, Timothy L.
- Published
- 2017
- Full Text
- View/download PDF
31. Can sinus anatomy predict quality of life outcomes and operative times of endoscopic frontal sinus surgery?
- Author
-
DeConde, Adam S., Barton, Michelle D., Mace, Jess C., and Smith, Timothy L.
- Published
- 2015
- Full Text
- View/download PDF
32. Biomimetic scaffolds facilitate healing of critical-sized segmental mandibular defects
- Author
-
Lee, Matthew K., DeConde, Adam S., Lee, Min, Walthers, Christopher M., Sepahdari, Ali R., Elashoff, David, Grogan, Tristan, Bezouglaia, Olga, Tetradis, Sotirios, St. John, Maie, and Aghaloo, Tara
- Published
- 2015
- Full Text
- View/download PDF
33. Modified Endoscopic Denker's Approach for Management of Anterior Maxillary Sinus Tumors: Multicenter Series of 58 Cases
- Author
-
McCormick, Justin P., primary, Suh, Jeffrey D., additional, Wang, Eric W., additional, DeConde, Adam S., additional, Wang, Marilene B., additional, Yang, Hong-Ho, additional, Carle, Taylor R., additional, Wung, Vivian, additional, and Lee, Jivianne T., additional
- Published
- 2022
- Full Text
- View/download PDF
34. Steroid-eluting Stent Placement for Refractory Stenosis of Parotid Megaduct After Sialodochoplasty
- Author
-
Bernstein, Jeffrey D., primary, DeConde, Adam S., additional, and Coffey, Charles S., additional
- Published
- 2022
- Full Text
- View/download PDF
35. Evaluating Surgeon-Specific Performance for Endoscopic Sinus Surgery
- Author
-
Rudmik, Luke, Xu, Yuan, Alt, Jeremiah A., Deconde, Adam, Smith, Timothy L., Schlosser, Rodney J., Quan, Hude, and Soler, Zachary M.
- Published
- 2017
- Full Text
- View/download PDF
36. Squamous cell carcinoma of buccal mucosa: a 40-year review
- Author
-
DeConde, Adam, Miller, Mia E., Palla, Beth, Lai, Chi, Elashoff, David, Chhetri, Dinesh, and St. John, Maie A.
- Published
- 2012
- Full Text
- View/download PDF
37. Outcomes of Surgical Treatment of Chronic Rhinosinusitis
- Author
-
DeConde, Adam S. and Alt, Jeremiah A.
- Published
- 2015
- Full Text
- View/download PDF
38. Open and endoscopic surgery improve survival for squamous and nonsquamous cell nasopharyngeal carcinomas: An NCDB cohort study
- Author
-
Finegersh, Andrey, primary, Said, Mena, additional, Deconde, Adam, additional, Hwang, Peter H., additional, Holsinger, Floyd Christopher, additional, and Orosco, Ryan K., additional
- Published
- 2022
- Full Text
- View/download PDF
39. Outcomes in Medical and Surgical Treatment of Nasal Polyps
- Author
-
Jafari, Aria, primary and DeConde, Adam S., additional
- Published
- 2016
- Full Text
- View/download PDF
40. Odontogenic Sinusitis
- Author
-
Chiu, Alexander, primary, Suh, Jeffrey, additional, and DeConde, Adam, additional
- Published
- 2016
- Full Text
- View/download PDF
41. Osteitis
- Author
-
Chiu, Alexander, primary, Suh, Jeffrey, additional, and DeConde, Adam, additional
- Published
- 2016
- Full Text
- View/download PDF
42. Measurements of health utility value in COVID‐19 olfactory dysfunction
- Author
-
Said, Mena, primary, Jang, Sophie S., additional, Luong, Thanh, additional, Bernstein, Jeffrey D., additional, DeConde, Adam S., additional, and Yan, Carol H., additional
- Published
- 2022
- Full Text
- View/download PDF
43. Impact of Race, Ethnicity, and Socioeconomic Status on Nasopharyngeal Carcinoma Disease-Specific and Conditional Survival
- Author
-
London, Ashley O., additional, Gallagher, Liam W., additional, Sharma, Rahul K., additional, Spielman, Daniel, additional, Golub, Justin S., additional, Overdevest, Jonathan B., additional, Yan, Carol H., additional, DeConde, Adam, additional, and Gudis, David A., additional
- Published
- 2021
- Full Text
- View/download PDF
44. Effect of Continued Medical Therapy on Productivity Costs for Refractory Chronic Rhinosinusitis
- Author
-
Rudmik, Luke, Soler, Zachary M., Smith, Timothy L., Mace, Jess C., Schlosser, Rodney J., and DeConde, Adam S.
- Published
- 2015
- Full Text
- View/download PDF
45. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
- Author
-
Han, Joseph K, primary, Bachert, Claus, additional, Fokkens, Wytske, additional, Desrosiers, Martin, additional, Wagenmann, Martin, additional, Lee, Stella E, additional, Smith, Steven G, additional, Martin, Neil, additional, Mayer, Bhabita, additional, Yancey, Steven W, additional, Sousa, Ana R, additional, Chan, Robert, additional, Hopkins, Claire, additional, Ahlström Emanuelsson, Cecilia, additional, Ardusso, Ledit, additional, Armstrong, Michael, additional, Bardin, Philip, additional, Barnes, Sara, additional, Bergna, Miguel, additional, Betz, Christian, additional, Beule, Achim, additional, Blotter, James, additional, Bronescu, Valeriu, additional, Brown, Matthew, additional, Carrie, Sean, additional, Chaker, Adam, additional, Cho, Hyung-Ju, additional, Corriveau, Marie-Noëlle, additional, Courville, Timothy, additional, Cuevas, Mandy, additional, Damask, Cecelia, additional, DeConde, Adam, additional, Del Carpio, Jaime, additional, De Salvo, María, additional, Dhong, Hun-Jong, additional, Durham, Stephen, additional, Edin, Anton, additional, Ehmer Jr, Dale, additional, Elías, Pedro, additional, Fatakia, Adil, additional, Franzese, Christine, additional, Gane, Simon, additional, García, Gabriel, additional, Gillman, Andrew, additional, Groeger, Moritz, additional, Harvey, Richard, additional, Hellgren, Johan, additional, Higgins, Thomas, additional, Hobson, Jonathan, additional, Jangard, Mattias, additional, Janjua, Arif, additional, Kara, Naveed, additional, Karpischenko, Sergey, additional, Kerwin, Edward, additional, Khanova, Fatimat, additional, Kilty, Shaun, additional, Kim, Chang-Hoon, additional, Kim, Seontae, additional, Klimek, Ludger, additional, LaForce, Craig, additional, Leong, Samuel, additional, Marple, Bradley, additional, Mårtensson, Anders, additional, Maspero, Jorge, additional, Massey, Neil, additional, Matz, Jonathan, additional, McDuffie, Chad, additional, Mella, Corina, additional, Miller, Steven, additional, Mirzabekyan, Ekaterina, additional, Moss, Jonathan, additional, Mumneh, Nayla, additional, Nathan, Robert, additional, Neagos, Adriana, additional, Olze, Heidi, additional, Ovchinnikov, Andrey, additional, Ow, Randall, additional, Polyakov, Dmitriy, additional, Radeanu, Doinel, additional, Rhee, Chae-Seo, additional, Rojas, Ramón, additional, Rosenbloom, Jeffrey, additional, Ryazantsev, Sergei, additional, Sader, Chady, additional, Saez Scherbovsky, Pablo, additional, Scadding, Guy, additional, Schlosser, Rodney, additional, Shah-Patel, Heena, additional, Shealy, Ronald, additional, Siddiqi, Ayesha, additional, Silvers, Stacey, additional, Singh, Narinder, additional, Sommer, Doron, additional, Soong, Weily, additional, Sowerby, Leigh, additional, Spafford, Peter, additional, Stefan, Catalin, additional, Sterling, Richard, additional, Svistushkin, Valeriy, additional, Talreja, Neetu, additional, Tarasova, Galina, additional, Tarpay, Martha, additional, Tolcachier, Alberto, additional, Toll, Karin Toll, additional, van Schaik, Carolina, additional, Webb, Luke, additional, Wedner, H James, additional, Wehbe, Luis, additional, Whan Kim, Soo, additional, Wollenberg, Barbara, additional, Wright, Simon, additional, Yakusevich, Vladimir, additional, Yañez, Anahí, additional, Yarin, Yury, additional, Yen, David, additional, and Yeol Kim, Hyo, additional
- Published
- 2021
- Full Text
- View/download PDF
46. Immunohistochemical and qPCR Detection of SARS-CoV-2 in the Human Middle Ear Versus the Nasal Cavity: Case Series
- Author
-
Kurabi, Arwa, primary, Pak, Kwang, additional, DeConde, Adam S., additional, Ryan, Allen F., additional, and Yan, Carol H., additional
- Published
- 2021
- Full Text
- View/download PDF
47. Quality of Life in Patients With Chronic Rhinosinusitis and Sleep Dysfunction Undergoing Endoscopic Sinus Surgery: A Pilot Investigation of Comorbid Obstructive Sleep Apnea
- Author
-
Alt, Jeremiah A., DeConde, Adam S., Mace, Jess C., Steele, Toby O., Orlandi, Richard R., and Smith, Timothy L.
- Published
- 2015
- Full Text
- View/download PDF
48. International Consensus Statement on Rhinology and Allergy: Rhinosinusitis
- Author
-
Orlandi, Richard, Kingdom, Todd T., Smith, Timothy L., Bleier, Benjamin, DeConde, Adam, Luong, Amber, Poetker, David M., Soler, Zachary, Welch, Kevin C., Wise, Sarah K., Adappa, Nithin, Alt, Jeremiah A., Anselmo-Lima, Wilma Terezinha, Bachert, Claus, Baroody, Fuad M., Batra, Pete S., Bernal-Sprekelsen, Manuel, Beswick, Daniel, Bhattacharyya, Neil, Chandra, Rakesh K., Chang, Eugene, Chiu, Alexander, Chowdhury, Naweed, Citardi, Martin J., Cohen, Noam, Conley, David B., DelGaudio, John, Desrosiers, Martin, Douglas, Richard, Anderson Eloy, Jean, Fokkens, Wytske J., Gray, Stacey T., Gudis, David A., Hamilos, Daniel L., Han, Joseph K., Harvey, Richard, Hellings, Peter, Holbrook, Eric H., Hopkins, Claire, Hwang, Peter, Javer, Amin R., Jiang, Rong-San, Kennedy, David, Kern, Robert, Laidlaw, Tanya, Lal, Devyani, Lane, Andrew, Lee, Heung-Man, Lee, Jivianne T., Levy, Joshua M., Lin, Sandra Y., Lund, Valerie, McMains, Kevin C., Metson, Ralph, Mullol, Joaquim, Naclerio, Robert, Oakley, Gretchen, Otori, Nobuyoshi, Palmer, James N., Parikh, Sanjay R., Passali, Desiderio, Patel, Zara, Peters, Anju, Philpott, Carl, Psaltis, Alkis J., Ramakrishnan, Vijay R., Ramanathan, Murugappan, Roh, Hwan-Jung, Rudmik, Luke, Sacks, Raymond, Schlosser, Rodney J., Sedaghat, Ahmad, Senior, Brent, Sindwani, Raj, Smith, Kristine, Snidvongs, Kornkiat, Stewart, Michael, Suh, Jeffrey, Tan, Bruce K., Turner, Justin H., van Drunen, Cornelis M., Voegels, Richard, Wang, De-Yun, Woodworth, Bradford A., Wormald, Peter-John, Wright, Erin D., Yan, Carol, Zhang, Luo, and Zhou, Bing
- Abstract
Background: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR‐RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR‐RS‐2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence‐based findings of the document. Methods: ICAR‐RS presents over 180 topics in the forms of evidence‐based reviews with recommendations (EBRRs), evidence‐based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary. Results: ICAR‐RS‐2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence‐based management algorithm is provided. Conclusion: This ICAR‐RS‐2021 executive summary provides a compilation of the evidence‐based recommendations for medical and surgical treatment of the most common forms of RS.
- Published
- 2021
49. Impact of Race, Ethnicity, and Socioeconomic Status on Nasopharyngeal Carcinoma Disease-Specific and Conditional Survival.
- Author
-
London, Ashley O., Gallagher, Liam W., Sharma, Rahul K., Spielman, Daniel, Golub, Justin S., Overdevest, Jonathan B., Yan, Carol H., DeConde, Adam, and Gudis, David A.
- Subjects
ETHNICITY ,RACE ,NASOPHARYNX cancer ,SOCIOECONOMIC status ,BLACK people ,COMBINED modality therapy - Abstract
Introduction Race, ethnicity, and socioeconomic status (SES) are complex, interconnected social determinants of health outcomes. This study uses multivariable analysis on a combination of large national datasets to examine the effects of these factors on 5-year disease-specific survival (DSS) and conditional DSS (CDSS) for nasopharyngeal carcinoma (NPC). Methods A retrospective study of adults with NPC between 2000 and 2017 from the Surveillance, Epidemiology, End Results (SEER) registry was performed, using the National Cancer Institute Yost Index, a census tract–level composite score of SES to categorize patients. Kaplan–Meier analysis and Cox's regression for DSS and CDSS were stratified by SES. Logistic regression was conducted to identify risk factors for advanced cancer stage at time of diagnosis and receiving multimodal therapy. Results Our analysis included 5,632 patients. DSS was significantly associated with race and SES (p < 0.01). Asian/Pacific Islander patients exhibited increased survival when controlling for other variables (hazard ratio [HR] = 0.73, p < 0.01). Although Black patients were more likely to be diagnosed with advanced disease (Black odds ratio [OR] = 1.47, p < 0.01), Black patients were also less likely to receive multimodal therapy; however, this relationship lost statistical significance once SES was incorporated into the multivariable analysis. DSS was decreased among the lowest (first) and middle (second) tertiles of SES (first HR = 1.34, p < 0.01; second HR = 1.20, p < 0.01) compared with the highest (third). Conclusion Our results indicate that race, ethnicity, and SES significantly affect survival, stage at diagnosis, and treatment of NPC. An interplay of tumor biology and inequalities in access to care likely drives these disparities. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Response Shift in Quality of Life After Endoscopic Sinus Surgery for Chronic Rhinosinusitis
- Author
-
DeConde, Adam S., Bodner, Todd E., Mace, Jess C., and Smith, Timothy L.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.